Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan
- PMID: 17327601
- PMCID: PMC2257989
- DOI: 10.1200/JCO.2006.07.4187
Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan
Abstract
Purpose: In patients with advanced colorectal cancer, leucovorin, fluorouracil, and irinotecan (FOLFIRI) is considered as one of the reference first-line treatments. However, only about half of treated patients respond to this regimen, and there is no clinically useful marker that predicts response. A major clinical challenge is to identify the subset of patients who could benefit from this chemotherapy. We aimed to identify a gene expression profile in primary colon cancer tissue that could predict chemotherapy response.
Patients and methods: Tumor colon samples from 21 patients with advanced colorectal cancer were analyzed for gene expression profiling using Human Genome GeneChip arrays U133. At the end of the first-line treatment, the best observed response, according to WHO criteria, was used to define the responders and nonresponders. Discriminatory genes were first selected by the significance analysis of microarrays algorithm and the area under the receiver operating characteristic curve. A predictor classifier was then constructed using support vector machines. Finally, leave-one-out cross validation was used to estimate the performance and the accuracy of the output class prediction rule.
Results: We determined a set of 14 predictor genes of response to FOLFIRI. Nine of nine responders (100% specificity) and 11 of 12 nonresponders (92% sensitivity) were classified correctly, for an overall accuracy of 95%.
Conclusion: After validation in an independent cohort of patients, our gene signature could be used as a decision tool to assist oncologists in selecting colorectal cancer patients who could benefit from FOLFIRI chemotherapy, both in the adjuvant and the first-line metastatic setting.
Figures


Similar articles
-
Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.Dis Colon Rectum. 2011 Aug;54(8):1026-35. doi: 10.1097/DCR.0b013e31821c44af. Dis Colon Rectum. 2011. PMID: 21730794
-
Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients.Clin Transl Oncol. 2011 Jun;13(6):419-25. doi: 10.1007/s12094-011-0676-z. Clin Transl Oncol. 2011. PMID: 21680303
-
A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.Oncology. 2007;73(1-2):9-20. doi: 10.1159/000120626. Epub 2008 Mar 11. Oncology. 2007. PMID: 18334829 Clinical Trial.
-
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.J Clin Oncol. 2007 May 1;25(13):1670-6. doi: 10.1200/JCO.2006.09.0928. J Clin Oncol. 2007. PMID: 17470860 Clinical Trial.
-
Chemotherapy of metastatic colorectal cancer.Prescrire Int. 2010 Oct;19(109):219-24. Prescrire Int. 2010. PMID: 21180382 Review.
Cited by
-
Clinical biomarkers in oncology: focus on colorectal cancer.Mol Diagn Ther. 2009;13(2):103-14. doi: 10.1007/BF03256319. Mol Diagn Ther. 2009. PMID: 19537845 Review.
-
A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.Mol Cancer Ther. 2012 Jan;11(1):119-31. doi: 10.1158/1535-7163.MCT-11-0510. Epub 2011 Oct 25. Mol Cancer Ther. 2012. PMID: 22027693 Free PMC article.
-
Reply to Colorectal cancer classification based on gene expression is not associated with FOLFIRI response.Nat Med. 2014 Nov;20(11):1231-2. doi: 10.1038/nm.3742. Nat Med. 2014. PMID: 25375919 No abstract available.
-
Highly informative marker sets consisting of genes with low individual degree of differential expression.Sci Rep. 2015 Oct 8;5:14967. doi: 10.1038/srep14967. Sci Rep. 2015. PMID: 26446398 Free PMC article.
-
5-FU promotes stemness of colorectal cancer via p53-mediated WNT/β-catenin pathway activation.Nat Commun. 2020 Oct 21;11(1):5321. doi: 10.1038/s41467-020-19173-2. Nat Commun. 2020. PMID: 33087710 Free PMC article.
References
-
- Weitz J, Koch M, Debus J, et al. Colorectal cancer. Lancet. 2005;365:153–65. - PubMed
-
- Vanhoefer U, Harstrick A, Achterrath W, et al. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol. 2001;19:1501–1518. - PubMed
-
- Pelley RJ. Oxaliplatin: a new agent for colorectal cancer. Curr Oncol Rep. 2001;3:147–155. - PubMed
-
- Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041–1047. - PubMed
-
- Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23–30. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases